Pharmacovigilance begins in 1968 with the 18th assembly of the World Health Organization (WHO). Currently, more than 50 nations participate in this program, including Mexico, which initiated Pharmacovigilance activities after the reforms made to the General Health Law in 1997 and to the decentralization of health services.
We are a company committed to comply with the health authority in the implementation of Pharmacovigilance, based on NOM-220-SSA-2012, through a Pharmacovigilance Unit recognized by the Secretary of Health (COFEPRIS).
Tecnovigilancia is defined as the set of activities that have as its objective the identification and qualification of serious and unwanted adverse effects produced by equipment and other medical devices, as well as the identification of the risk factors associated with these effects or characteristics, with based on the notification, registration and systematic evaluation of the problems related to medical devices, in order to determine the frequency, severity and incidence of the same to prevent their occurrence.
We are a company that is committed to comply with the health authority, in the implementation of Tecnovigilancia based on NOM-240-SSA-2012, through a Tecnovigilancia Unit recognized by the Ministry of Health (COFEPRIS), with which It aims to make better use of Biomedical technology and other medical devices, avoiding adverse incidents in the institution.
Adverse incidents caused by medical devices, due to their social and economic repercussions, are monitored by the Tecnovigilancia program due to injuries and / or pathologies that may occur to patients, operators or any other person.